Advair generic 70% discount...

Discussion in 'AstraZeneca' started by anonymous, Feb 13, 2019 at 8:36 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

  2. anonymous

    anonymous Guest

  3. anonymous

    anonymous Guest

    Not good. Not good one bit.

    Symbicort brand team: Thinking you will need to go back to "guarantee program" and significant relaxation of FTO's to stand a chance. Otherwise, DOA.
     
  4. anonymous

    anonymous Guest

    Seriously, what is the point? If we do get business, it’s worthless and certainly not worth the ROI to promote...
     
  5. anonymous

    anonymous Guest

    I wonder if they’ll pull DTC....
     
  6. anonymous

    anonymous Guest

    Well they’ve already pulled a majority of our samples!! Soooo.....
     
  7. anonymous

    anonymous Guest

    This is not good at all:(! Mylan with a very cheap generic and GSK launching one too! Ugh!!!
     
  8. anonymous

    anonymous Guest

    waiting for an update for our RTCF with the latest information of a 70% reduction to WAC when we expected 13-15% WHEN THE FDA ABgeneric approved. Has anyone heard from your leadership how we RTCF OR IF WE EXPECT Step therapy due to a low-cost generic being available for first time?? Crickets
     
  9. anonymous

    anonymous Guest

    70%!!!
    Face it, there is ZERO reason to promote anymore. No company has ever promoted against a generic with this steep a discount, nor will they. All investment in the brand will be done within 30 days.
     
  10. anonymous

    anonymous Guest

    Of course there are crickets. That’s all we’ve heard for the past two plus years of this idiotic leadership in place. Biggest event to happen in our market and do you think we’d hear for them about preparedness or strategy?? No....instead we had to listen to DF and MH giggle like a bunch of immature sorority girls on the fast start call, instead of hearing what the plan was!!
     
  11. anonymous

    anonymous Guest

    Just listened to the 2018 global webcast on results. During Q&A, Ruud took question around AB generic Advair. His response was priceless. Said it is very difficult to determine impact (BS) and that it is a different device and different molecules. Ruud, at a 70% discount, how much do you think managed care orgs will give 2 poops about what device the drug is delivered in? He knows as we all do, Symbicort will lose a lot more than the 22% it lost in 2018 due to "pricing pressures". Expect a WARN notice by mid-year I would guess and a revamp on what product will be numero uno. Bevespi will save those who are left! Yeah right.
     
  12. anonymous

    anonymous Guest

    Real question is how many respiratory reps do they need to sell the triple and the Saba. I’m thinking not as many as they have now.
     
  13. anonymous

    anonymous Guest

    Dont forget Daliresp :D
     
  14. anonymous

    anonymous Guest

    Clearly gsk still need a shit ton of reps to promote tril and incruse! They already supposedly did their realignment and their reps are still crawling all over the place - smaller territories than ours and with more reps! Cant grow products without people to promote them and our portfolio is still plenty full with Dali Bev PulmFh Symb Triple and Saba to come!! Not to mention they've already tried the genius move of pulling share of voice out of pulm a few years back and then numbers tanked in that segment, Proof that we must be doing something valuable!!
     
  15. anonymous

    anonymous Guest

     
  16. anonymous

    anonymous Guest

    what are you talking about? The AB rated products are the EXACT SAME as branded Advair (unlike Airduo). Agree that. Payers don’t care about device, indications, etc. it comes down to the $$. Perfect example is Dulera w/out a COPD indication. Do hospitals care...nope...it’s about $$. Outlying question..will payers put a ST on branded products to try Mylan generic first due to cost???
     
  17. anonymous

    anonymous Guest

    You know the answer to that question. Oui!
     
  18. anonymous

    anonymous Guest

    Mylan isn’t the only generic. Gsk is making a generic that is being marketed and sold by Prasco. Same drug, same device but different name. Going to get interesting soon. Two generics.
     
  19. anonymous

    anonymous Guest

    Interesting??
    How?
    There are now two generics in the market selling at 70% lower than any ics/laba was last week. Payers already have what they are doing loaded...it’s the flick of a switch. As soon as the generics are loaded in channel (face it, GSKs will take ZERO time) there will be a step edit in place.
    If any of you think you’ll have Symb in the bag after 4/1, you’re delusional.
     
  20. anonymous

    anonymous Guest

    Only Mylan's is priced at a 70% discount. And although AB rated is not the same device. Gut reaction tells me that something is fishy with Mylan's product. Why else would you leave that much $ on the table when a 30% discount would accomplish the same thing? Lets wait and see if this thing actually deserves its AB rating.

    In the meantime, it would be wise for brand to bring back "guarantee" program to assist in handling what will be a strong push by MCO's to use generic. Also, with many IDN's moving away from samples and GSK (no ridiculously tiny limits imposed by their HQ) flooding offices with their own vouchers, significantly increasing our FTO's will help where generics won't have that resource.
     

play:inline;">